Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Letters to the Editor

Efficacy of Zibotentan in Colorectal Cancer—Letter

Panagiotis J. Vlachostergios
Panagiotis J. Vlachostergios
Department of Internal Medicine, Lutheran Medical Center, Brooklyn, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-13-0819 Published June 2014
  • Article
  • Info & Metrics
  • PDF
Loading

In their study, Haque and colleagues evaluate the specific endothelin A receptor (ETAR) antagonist zibotentan in colorectal cancer cellular models with relevance to proliferation and migration potential of tumor cells and stromal fibroblasts. Interestingly, they demonstrate that ETAR is the principal receptor used by ET-1 and provide evidence for involvement of stromal fibroblasts in cancer progression as targets of ET-1 signaling. Given zibotentan had the greatest inhibitory effect on ET-1 signaling, the authors suggest a potential role of the drug in adjuvant therapy of colorectal cancer (1). These data are further confirmed by more recent evidence that ET-1 signaling through ETAR promotes liver metastasis in colorectal cancer (2).

The model of aberrant ET-1 signaling in colorectal cancer seems to share many similarities with that of prostate cancer, given the endothelin axis has also been implicated in progression from androgen-sensitive to androgen-independent state (3). However, it remains elusive why encouraging preclinical data on zibotentan were not replicated at the clinical level about prostate cancer treatment. This was not only observed in the metastatic but also in the nonmetastatic setting (4).

Notably, in addition to ETAR, ET-1 mediates its signaling effects through transactivation or direct activation of several pathways, such as PI3K/Akt, contribution of which is often underscored at the preclinical level (5). Thus, a consideration for specific ET-1 inhibition rather than ETAR antagonism might be more reasonable in terms of achieving a wider targeting of ET-1 signaling. In addition, several factors that interfere with ET-1 signaling within the tumor microenvironment, such as intratumoral hypoxia, are not taken into account when designing targeted treatments. In that perspective, a combined strategy might be more successful in establishing more efficient inhibition of the endothelin axis.

Another issue that remains to be answered is identification of a surrogate marker of response for this targeted treatment. Previous testing of serum ET-1 levels or plasma big ET-1 in patients with colorectal cancer has not yielded consistent results about their prognostic or predictive value (6). This might at least partially be attributed to their non–cancer-specific association with hypertension. Finally, little is known about the effect of antiangiogenic and/or anti–EGFR-targeted treatments on ET-1 signaling at the colorectal cancer metastatic setting.

It would, therefore, be interesting to see whether the failure of zibotentan to provide significant improvement in overall survival of patients with prostate cancer is replicated or not in the case of colorectal cancer. Results from the ongoing phase II study of zibotentan added to FOLFIRI for patients with metastatic colorectal cancer are eagerly awaited. Notably, given preclinical implications for an antimetastatic role of zibotentan (1, 2), the design of a study testing the drug in the adjuvant setting as an adjunct to established regimens would also be helpful to decipher whether intervention to the endothelin axis in colorectal cancer may actually delay relapse of disease.

See the Response, p. 1674

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

  • Received October 3, 2013.
  • Revision received December 5, 2013.
  • Accepted December 12, 2013.
  • ©2014 American Association for Cancer Research.

References

  1. 1.↵
    1. Haque SU,
    2. Dashwood MR,
    3. Heetun M,
    4. Shiwen X,
    5. Farooqui N,
    6. Ramesh B,
    7. et al.
    Efficacy of the specific endothelin A receptor antagonist zibotentan (ZD4054) in colorectal cancer: a preclinical study. Mol Cancer Ther 2013;12:1556–67.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Nie S,
    2. Zhou J,
    3. Bai F,
    4. Jiang B,
    5. Chen J,
    6. Zhou J
    . Role of endothelin a receptor in colon cancer metastasis: in vitro and in vivo evidence. Mol Carcinog 2013;53 Suppl 1:E85–91
    OpenUrlPubMed
  3. 3.↵
    1. Vlachostergios PJ,
    2. Karasavvidou F,
    3. Kakkas G,
    4. Moutzouris G,
    5. Patrikidou A,
    6. Voutsadakis IA,
    7. et al.
    Expression of neutral endopeptidase, endothelin-1, and nuclear factor kappa B in prostate cancer: interrelations and associations with prostate-specific antigen recurrence after radical prostatectomy. Prostate Cancer 2012;2012:452795.
    OpenUrlPubMed
  4. 4.↵
    1. Miller K,
    2. Moul JW,
    3. Gleave M,
    4. Fizazi K,
    5. Nelson JB,
    6. Morris T,
    7. et al.
    Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with nonmetastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2013;16:187–92.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Bouallegue A,
    2. Daou GB,
    3. Srivastava AK
    . Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr Vasc Pharmacol 2007;5:45–52.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Lloyd GM,
    2. Neal CP,
    3. Arun C,
    4. London NJ,
    5. Hemingway DM
    . The prognostic value of circulating big endothelin-1 in patients undergoing potentially curative resection for colorectal cancer. Colorectal Dis 2011;13:290–5.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Molecular Cancer Therapeutics: 13 (6)
June 2014
Volume 13, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy of Zibotentan in Colorectal Cancer—Letter
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Efficacy of Zibotentan in Colorectal Cancer—Letter
Panagiotis J. Vlachostergios
Mol Cancer Ther June 1 2014 (13) (6) 1673; DOI: 10.1158/1535-7163.MCT-13-0819

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Efficacy of Zibotentan in Colorectal Cancer—Letter
Panagiotis J. Vlachostergios
Mol Cancer Ther June 1 2014 (13) (6) 1673; DOI: 10.1158/1535-7163.MCT-13-0819
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Disclosure of Potential Conflicts of Interest
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • PDT with a Glucose-Conjugated Chlorin for GIST—Letter
  • PDT with a Glucose-Conjugated Chlorin for GIST—Response
Show more Letters to the Editor
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement